Journal of Gastroenterology
Cure8 research brief
Why This Matters
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
Researchers also identified a fibroblast-derived marker (MMP13) that could help explain resistance mechanisms and might become a future biomarker or therapeutic target.
Who Should Pay Attention
Clinicians managing biologic sequencing for ulcerative colitis, researchers studying treatment resistance or biomarkers, and adult patients considering or starting ustekinumab—especially those with prior vedolizumab exposure.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The clinical finding is association-only from retrospective data — prior vedolizumab exposure was independently associated with nonresponse to ustekinumab but does not prove causation.
The molecular work used colonic tissue profiling and fibroblast stimulation to nominate MMP13 as a fibroblast-derived marker tied to nonresponse; this points toward an IL‑1β–linked inflammatory fibroblast state rather than providing a validated predictive test.
How patients might use this: Patients and clinicians may consider prior treatment history when discussing expected response to ustekinumab, but this study doesn’t establish treatment sequencing rules. The MMP13 finding is hypothesis-generating and would need prospective validation before guiding care.
Source and depth: Findings are reported in a Journal of Gastroenterology article; the Cure8 brief is based on the article abstract and reported molecular analyses.
Keep In Mind
This is a retrospective multicenter study with transcriptomic and in vitro experiments; associations do not prove causation. The MMP13 signal is exploratory and requires prospective validation before clinical use. The Cure8 summary is grounded in the article abstract (structured content depth: abstract).
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Gastroenterology
PublisherSpringer Science and Business Media LLC
AuthorsYuiko Tsuruta, Yoki Furuta, Masatoshi Nakashima +22 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 28, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Japan Society for the Promotion of Science, award 23K15014
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
Management of Arthritis Associated with Inflammatory Bowel Disease (IBD): A Systematic Review of Conventional and Targeted Therapies
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.